KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) Equity Income (2017 - 2020)

Fulgent Genetics (FLGT) has disclosed Equity Income for 4 consecutive years, with $143000.0 as the latest value for Q4 2020.

  • Quarterly Equity Income rose 182.18% to $143000.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was -$488000.0 through Dec 2020, up 37.19% year-over-year, with the annual reading at -$488000.0 for FY2020, 37.19% up from the prior year.
  • Equity Income hit $143000.0 in Q4 2020 for Fulgent Genetics, up from -$189000.0 in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $143000.0 in Q4 2020 to a low of -$279000.0 in Q1 2019.
  • Historically, Equity Income has averaged -$181600.0 across 4 years, with a median of -$193000.0 in 2020.
  • Biggest five-year swings in Equity Income: plummeted 134.29% in 2018 and later skyrocketed 182.18% in 2020.
  • Year by year, Equity Income stood at -$247000.0 in 2017, then grew by 5.26% to -$234000.0 in 2018, then increased by 25.64% to -$174000.0 in 2019, then surged by 182.18% to $143000.0 in 2020.
  • Business Quant data shows Equity Income for FLGT at $143000.0 in Q4 2020, -$189000.0 in Q3 2020, and -$193000.0 in Q2 2020.